EQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase excluding statutory subscription rights | 02.09.24

Korneuburg, Austria, September 2, 2024 – Marinomed Biotech AG (the “Company”) announces that its Board of Directors has today decided to evaluate a capital increase of up to 154,053 new shares to be issued from the Authorized Capital 2024, subject to the immediate exclusion of statutory subscription rights of existing shareholders, to finance ongoing costs in the restructuring procedures, to finance part of the restructuring plan proposal and for costs of continuing operations. This corresponds to up to 10% of the Company’s existing share capital.

For the purpose of the evaluation, the Board of Management will hold discussions with selected investors regarding the potential transaction and the transaction documentation. The actual implementation of the capital increase depends on the outcome of these discussions and is subject to further decision-making by the Board of Management and approval by the Supervisory Board. In addition, the restructuring procedures require the approval of the restructuring manager. These approvals have not yet been obtained.

If the capital increase is implemented, the Board of Directors will consider a possible second capital increase of 10% of the existing share capital of the Company, excluding the statutory subscription rights of existing shareholders.

+++ End of ad-hoc announcement +++